• Home
  • Shop
  • About
  • FAQ
  • Contact
  • Compare Peptides
  • Wholesale
  • CJC-1295 with DAC: Complete Research Guide — Mechanisms, Studies & Analysis

    Research Use Only — Informational Content: The information in this article is intended for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Iron Peak Peptides products are strictly for laboratory and scientific research — not for human consumption. Consult a licensed healthcare provider before starting any treatment or therapy. These statements have not been evaluated by the FDA.

    CJC 1295 DAC Peptide Research: Complete Guide — Mechanisms, Studies & Analysis

    Meta Description: CJC-1295 DAC is a long-acting GHRH analog with a 6–8 day half-life. Explore the science, research findings, and quality standards for this research peptide.

    Target Keywords: cjc 1295 dac, cjc 1295 with dac, cjc with dac, what is dac in peptides, cjc dac, cjc-1295 dac

    Table of Contents

    What Is CJC-1295 DAC?

    CJC-1295 DAC is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) engineered with a Drug Affinity Complex (DAC) that dramatically extends its biological half-life. Also referred to as DAC:GRF (Drug Affinity Complex: Growth Hormone-Releasing Factor), this 30-amino-acid peptide represents one of the most significant innovations in GHRH analog research, offering an estimated half-life of 6 to 8 days compared to the mere minutes observed with native GHRH [1, 3].

    Originally developed by ConjuChem Biotechnologies, CJC-1295 DAC was designed to overcome the primary limitation of endogenous GHRH and early synthetic analogs: rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) in plasma, which cleaves GHRH at the 2–3 amino acid bond within minutes of release [1, 16]. Through a combination of strategic amino acid substitutions and the addition of the proprietary DAC moiety, CJC-1295 DAC achieves sustained activity, stimulating the pituitary gland to release growth hormone and thereby increasing growth hormone levels in a controlled and physiological manner. This longer half-life has made it one of the most studied peptides in growth hormone (GH) axis research.

    Research indicates that a single administration of CJC-1295 DAC may increase mean plasma GH concentrations by 2- to 10-fold for 6 days or longer, and plasma insulin-like growth factor 1 (IGF-I) levels by 1.5- to 3-fold for 9 to 11 days [3]. These sustained elevations, combined with preserved pulsatile GH secretion patterns, distinguish CJC-1295 DAC as a uniquely valuable tool for investigating the GH/IGF-1 axis in preclinical and research settings. Unlike synthetic growth hormone or synthetic hGH therapies, which provide exogenous hormone, CJC-1295 DAC promotes endogenous hormone release by mimicking the natural GHRH signal.

    CJC-1295 DAC is being actively investigated for its potential to produce deep, restorative sleep, as well as for its applications in cellular-aging, obesity, muscle loss, and performance enhancement research. Growth hormone deficiency can lead to increased body fat, and CJC-1295 DAC is being researched for its potential to address this by normalizing growth hormone levels.

    For researchers seeking to investigate long-acting GHRH analogs in the laboratory, Iron Peak Peptides offers high-purity CJC-1295 with DAC verified through strict quality standards.

    What Is DAC in Peptides? Understanding the Drug Affinity Complex

    One of the most frequently asked questions in peptide research is: what is DAC in peptides? The Drug Affinity Complex (DAC) is a bioconjugation technology developed by ConjuChem Biotechnologies that enables peptides to bind covalently to endogenous serum albumin after administration, dramatically extending their circulating half-life [1, 6].

    The Chemistry of DAC Technology

    The DAC in CJC-1295 consists of a maleimidopropionic acid (MPA) linker conjugated to a lysine residue (Lys-30) appended to the C-terminus of the modified GRF (1-29) backbone. The complete IUPAC modification nomenclature for CJC-1295 DAC is:

    Nε30-maleimidopropionyl-[D-Ala2, Gln8, Ala15, Leu27]-Sermorelin-Lys30

    Here is how the DAC bioconjugation process works:

    1. Reactive Maleimide Group: The MPA moiety contains a reactive maleimide functional group that is designed to undergo a Michael addition reaction with nucleophilic thiol groups.

    2. Extended Circulation: Once bound to albumin (molecular weight ~67 kDa), the peptide-albumin bioconjugate is too large for rapid renal clearance and is protected from enzymatic degradation, extending the effective half-life from minutes to approximately 6–8 days [3].

    This approach to half-life extension represents one of the earliest successful applications of albumin-binding bioconjugation in peptide design, a principle that has since influenced the development of numerous long-acting therapeutic peptides and proteins across pharmacology.

    Why Albumin Binding Matters

    Serum albumin is the most abundant protein in human plasma, with a circulating half-life of approximately 19–21 days. By piggybacking on albumin’s natural longevity, the DAC technology effectively transforms a rapidly degraded peptide into a long-acting compound. Research by Jetté et al. (2005) demonstrated that after administration, CJC-1295 forms a 1:1 bioconjugate with serum albumin, and that this bioconjugate retains full biological activity at the GRF receptor on anterior pituitary cells [1].

    The Science Behind CJC-1295 with DAC: Mechanism of Action

    Understanding how CJC-1295 with DAC functions requires knowledge of both the GH/IGF-1 endocrine axis and the specific molecular interactions through which this peptide exerts its effects. CJC-1295 acts as a GHRH analog, stimulating endogenous gh production by acting on somatotroph cells in the pituitary gland. By mimicking the natural GHRH signal, CJC-1295 prompts the pituitary gland to release growth hormone. This increased gh production leads to enhanced protein synthesis, muscle growth, and tissue repair, helping to increase muscle mass and support muscle gain. Studies have shown that CJC-1295 can lead to significant increases in muscle mass and strength, particularly in older adults, by enhancing protein synthesis and promoting recovery from exercise. As a result, downstream effects include increases in muscle mass and lean mass, improvements in fat metabolism, fat loss, weight loss, and enhanced physical performance. In some cases, weight gain may occur due to increases in muscle and bone mineral content. Studies indicate that CJC-1295 can lead to a reduction in body fat, particularly visceral fat, while promoting lean muscle mass. Additionally, growth hormone and IGF-1 stimulate collagen synthesis and collagen production, which are vital for tissue repair and maintaining skin health. CJC-1295 may also support cellular proliferation and immune system function, as observed in some studies. The field of clinical endocrinology studies these hormone pathways and their therapeutic modulation, providing the foundation for understanding the metabolic and regenerative benefits of peptides like CJC-1295.

    The GH/IGF-1 Axis: A Brief Overview

    Growth hormone secretion from the anterior pituitary gland is regulated by a dynamic interplay between two hypothalamic peptides:

    • Growth Hormone-Releasing Hormone (GHRH): A 44-amino-acid peptide that stimulates GH synthesis and secretion from pituitary somatotroph cells

    • Somatostatin (SST): An inhibitory peptide that suppresses GH release

    This push-pull regulatory mechanism produces the characteristic pulsatile pattern of GH secretion, with major secretory bursts occurring during deep sleep and following exercise or fasting [5, 13].

    GHRH Receptor Activation and Signaling

    CJC-1295 DAC exerts its primary effects by binding to the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotroph cells. The GHRHR is a class B G protein-coupled receptor (GPCR) that, upon ligand binding, activates the following intracellular signaling cascade:

    1. Gαs Protein Coupling: GHRHR activation stimulates the Gαs subunit of heterotrimeric G proteins

    2. Adenylyl Cyclase Activation: Gαs stimulates adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations

    3. PKA Activation: Elevated cAMP activates protein kinase A (PKA)

    4. CREB Phosphorylation: PKA phosphorylates the cAMP response element-binding protein (CREB), promoting transcription of the GH gene

    5. Calcium Influx: PKA also opens voltage-gated calcium channels, triggering the exocytosis of GH-containing secretory granules [13, 14]

    The net result is both acute GH release from preformed secretory vesicles and longer-term upregulation of GH gene transcription and somatotroph proliferation.

    Amino Acid Modifications for Stability

    Beyond the DAC moiety, CJC-1295 incorporates four key amino acid substitutions compared to native GHRH (1-29) (sermorelin):

    Position

    Native GHRH

    CJC-1295

    Purpose

    2

    Ala (L)

    D-Ala

    DPP-IV resistance

    8

    Asn

    Gln

    Prevents asparagine deamidation

    15

    Gly

    Ala

    Enhances receptor binding affinity

    27

    Met

    Leu

    Prevents methionine oxidation

    These substitutions collectively render the peptide backbone resistant to DPP-IV cleavage (the primary route of GHRH degradation) while maintaining full agonist activity at the GHRHR [1, 3, 16]. The replacement of methionine at position 27 with leucine is particularly important for research applications, as methionine oxidation is a common source of peptide degradation during storage and handling.

    Sustained GH Secretion with Preserved Pulsatility

    A critical finding from CJC-1295 DAC research is that the compound produces sustained GH elevation while preserving the normal pulsatile pattern of GH secretion. Ionescu and Frohman (2006) demonstrated in a clinical study that after CJC-1295 administration, GH pulsatile frequency and pulse amplitude were maintained, but basal (trough) GH levels were markedly increased by approximately 7.5-fold (P < 0.0001) [5].

    This is physiologically significant because:

    • Pulsatile GH secretion is considered essential for many of GH’s downstream effects, including linear growth and metabolic regulation

    • Continuous, non-pulsatile GH elevation (as seen with exogenous GH administration) can lead to receptor desensitization

    • CJC-1295 DAC appears to amplify the normal secretory pattern rather than replacing it with a pharmacological override, suggesting it works in concert with endogenous somatostatin-mediated feedback [5]

    Development History: From ConjuChem to Modern Research

    The story of CJC-1295 DAC is intertwined with the broader history of GHRH analog development and the innovative work of ConjuChem Biotechnologies, a Canadian biopharmaceutical company that pioneered the Drug Affinity Complex (DAC™) platform.

    The Challenge of GHRH Therapy

    By the early 2000s, researchers had long recognized the therapeutic potential of GHRH for conditions involving GH deficiency. However, native GHRH is rapidly degraded by DPP-IV in plasma, with a circulating half-life of only 7–10 minutes [16]. This severe limitation meant that even sermorelin — the synthetic GHRH (1-29) fragment approved for diagnostic and research use — required frequent administration and produced only transient GH elevations.

    ConjuChem’s DAC™ Platform

    ConjuChem Biotechnologies developed the DAC™ technology as a general platform for extending peptide half-lives through in vivo albumin bioconjugation. CJC-1295 (known internally as the DAC™:GRF compound) was among the first peptides engineered using this platform [1, 6].

    Key milestones in CJC-1295 DAC development include:

    • 2004–2005: Jetté, Léger, Thibaudeau, and colleagues published the foundational preclinical characterization of CJC-1295, demonstrating that hGRF(1-29)-albumin bioconjugates activated the GRF receptor on rat anterior pituitary cells and identifying CJC-1295 as a long-lasting GRF analog [1]

    • 2006: Teichman et al. published results from two randomized, placebo-controlled, double-blind trials in healthy adults, establishing the pharmacokinetic and pharmacodynamic profile of CJC-1295 [3]

    • 2006: Alba et al. demonstrated that once-daily CJC-1295 administration normalized growth in GHRH knockout mice, providing proof of concept for its sustained GHRH-like activity [2]

    • 2006: Ionescu and Frohman published the landmark GH pulsatility study confirming preserved pulsatile secretion during CJC-1295 stimulation [5]

    • 2006: Clinical development was halted after a patient death during Phase II trials for lipodystrophy; the attending physician assessed the event as likely unrelated to CJC-1295 (attributed to pre-existing asymptomatic coronary artery disease), but trials were discontinued as a precaution [11, 12]

    • 2009: Sackmann-Sala et al. published proteomic analysis showing CJC-1295-induced GH/IGF-1 axis activation resulted in characteristic serum protein profile changes [10]

    ConjuChem Biotechnologies is now defunct, but CJC-1295 DAC remains one of the most widely studied GHRH analogs in the research community, and the DAC technology continues to influence peptide engineering strategies.

    Key Research Findings on CJC-1295 DAC

    The scientific literature on CJC-1295 DAC encompasses preclinical animal studies, human pharmacokinetic trials, and proteomic investigations. Clinical research, often guided by standards set by the Endocrine Society, has established the foundation for growth hormone therapy and peptide tesearch protocols. Below, we examine the major research areas and the studies that define our current understanding of this peptide, with researchers actively exploring peptide tesearch for its potential in cellular-aging, athletic performance, recovery, and body composition.

    Pharmacokinetics and Half-Life Extension

    The most consequential feature of CJC-1295 DAC is its dramatically extended half-life. Teichman et al.

    • Estimated half-life: 5.8 to 8.1 days (compared to ~7 minutes for native GHRH)

    • IGF-1 elevation duration: Mean plasma IGF-1 concentrations increased 1.5- to 3-fold for 9–11 days

    • Cumulative effect: With multiple administrations, IGF-1 levels remained elevated above baseline for up to 28 days

    • Safety profile: No serious adverse events were reported in either trial

    These findings demonstrated an approximately 700- to 1,000-fold increase in functional half-life compared to native GHRH, representing one of the most successful examples of bioconjugation-based half-life extension in peptide pharmacology.

    Growth Hormone Pulsatility Research

    The preservation of GH pulsatility during CJC-1295 DAC stimulation is among the peptide’s most scientifically significant properties. Ionescu and Frohman (2006) assessed GH pulsatility using 20-minute blood sampling during 12-hour overnight periods before and one week after CJC-1295 administration in healthy men ages 20–40 [5]:

    Key findings:

    • GH pulse frequency was unchanged

    • GH pulse amplitude was preserved

    • Basal (trough) GH levels increased 7.5-fold (P < 0.0001)

    • Mean overall GH secretion increased by 46% (P < 0.01)

    • IGF-1 levels increased by 45% (P < 0.001)

    • The increase in IGF-1 did not correlate with specific GH pulse parameters, suggesting trough GH elevation was the primary driver of IGF-1 production

    This study provided critical evidence that CJC-1295 DAC operates through the physiological GHRH pathway rather than bypassing normal regulatory mechanisms. The preserved pulsatility suggests that endogenous somatostatin feedback remains intact during CJC-1295 stimulation, distinguishing it from exogenous GH administration.

    Preclinical Growth Normalization Studies

    Alba, Fintini, Sagazio, and colleagues (2006) conducted a pivotal study using GHRH knockout (GHRHKO) mice — animals that lack endogenous GHRH production and exhibit severe GH deficiency, dwarfism, and reduced lean body mass [2].

    Study design and findings:

    • GHRHKO mice received once-daily CJC-1295 administration

    • Treatment normalized body weight and body composition to levels comparable to wild-type littermates

    • CJC-1295 increased total pituitary RNA and GH mRNA expression

    • Histological analysis confirmed increased somatotroph proliferation

    GRF Receptor Activation and Bioconjugate Activity

    The foundational mechanistic study by Jetté, Léger, Thibaudeau, and colleagues (2005) characterized the receptor pharmacology of CJC-1295 and its albumin bioconjugates [1]:

    • Multiple hGRF(1-29)-MPA analogs were synthesized and tested for GRF receptor activation on rat anterior pituitary cells

    • CJC-1295 was identified as the lead compound based on optimal receptor binding and bioconjugation efficiency

    • The albumin-CJC-1295 bioconjugate retained full GRF receptor agonist activity

    • In vivo studies in rats confirmed that CJC-1295 formed albumin bioconjugates in circulation and produced prolonged GH elevation

    • The bioconjugation was confirmed to be covalent and irreversible under physiological conditions

    Serum Protein Profile Changes

    Sackmann-Sala, Ding, Frohman, and Kopchick (2009) investigated the broader proteomic effects of CJC-1295-induced GH/IGF-1 axis activation in healthy adult subjects [10]:

    • Sera from 11 healthy subjects treated with CJC-1295 were analyzed using two-dimensional gel electrophoresis

    • Multiple serum proteins showed significant changes in expression levels following CJC-1295 administration

    • Protein changes were consistent with known effects of GH/IGF-1 axis activation

    • The findings provided evidence that CJC-1295 produces physiologically relevant downstream effects beyond simple GH and IGF-1 elevation

    • Results supported the use of protein biomarker profiling for monitoring GH axis status in research settings

    CJC-1295 DAC vs. CJC-1295 Without DAC (Mod GRF 1-29)

    A common source of confusion in the peptide research community is the distinction between CJC-1295 DAC and CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29). While the names are similar, these are structurally and functionally distinct molecules with fundamentally different pharmacokinetic profiles.

    Slow wave sleep is the deepest and most restorative stage of sleep, and studies indicate that higher GHRH activity can decrease wakefulness and promote improved deep sleep. This enhancement of slow wave sleep leads to better sleep overall, supporting recovery, mental clarity, and natural growth hormone secretion. Improved sleep quality and better sleep are considered positive effects associated with CJC-1295 peptide research, further contributing to its appeal in scientific and clinical studies.

    Structural Differences

    Feature

    CJC-1295 DAC

    CJC-1295 Without DAC (Mod GRF 1-29)

    Amino acids

    30 (includes Lys-30 with MPA)

    29

    DAC moiety

    Present (Nε-maleimidopropionyl-Lys30)

    Absent

    Albumin binding

    Yes (covalent)

    No

    Half-life

    6–8 days

    ~30 minutes

    Molecular formula

    C₁₆₅H₂₆₉N₄₇O₄₆

    C₁₅₂H₂₅₂N₄₄O₄₂

    Molecular weight

    ~3,647 Da

    ~3,367 Da

    Core modifications

    D-Ala2, Gln8, Ala15, Leu27

    D-Ala2, Gln8, Ala15, Leu27

    Both peptides share the same four amino acid substitutions relative to native sermorelin (GHRH 1-29), which confer DPP-IV resistance and improved stability [3, 7]. The critical difference is the presence or absence of the 30th amino acid (lysine) bearing the maleimidopropionic acid linker.

    Functional Differences in Research

    The choice between CJC-1295 with DAC and CJC-1295 without DAC (Mod GRF 1-29) depends on the research objectives:

    CJC-1295 DAC is preferred when:

    • Investigating sustained, long-duration GH/IGF-1 axis stimulation

    • Studying chronic GH elevation models

    • Modeling continuous GHRH-like signaling

    • Evaluating cumulative effects of prolonged GH axis activation

    • Conducting studies where less frequent administration is desirable

    Mod GRF 1-29 (without DAC) is preferred when:

    • Studying acute, pulsatile GH release patterns

    • Modeling physiological GHRH burst patterns

    • Investigating GHRH-GHRP synergy with precise timing control

    • Studying rapid-onset, short-duration GH secretion dynamics

    • Designing protocols that require tight temporal control over GH peaks

    For researchers interested in comparing these two peptides directly, Iron Peak Peptides supplies both CJC-1295 with DAC and standard Mod GRF 1-29 to support diverse experimental designs.

    A Note on Nomenclature

    It is important for researchers to be aware that CJC-1295, CJC-1295 DAC, and CJC-1295 with DAC are all synonymous terms referring to the same 30-amino-acid peptide with the maleimidopropionyl-lysine DAC extension [7, 3]. The colloquial term “CJC-1295 without DAC” refers to Modified GRF (1-29), which lacks the C-terminus extension. Several scientific papers have incorrectly equated these two distinct molecules, leading to confusion in the literature [7, 15].

    Comparing CJC-1295 DAC with Sermorelin and Tesamorelin

    CJC-1295 DAC belongs to a broader class of GHRH analogs that also includes sermorelin and tesamorelin. Understanding the structural and functional differences among these peptides is essential for designing appropriate research protocols. Researchers can explore all available GHRH analogs in our comprehensive peptide glossary.

    Sermorelin (GHRH 1-29)

    Sermorelin is the unmodified synthetic form of the first 29 amino acids of human GHRH. It retains full biological activity because the bioactive core of GHRH resides within residues 1–29, while residues 30–44 primarily contribute to stability rather than receptor binding [17].

    Key characteristics:

    • 29 amino acids, identical to native GHRH (1-29)

    • Half-life: approximately 10–20 minutes

    • Susceptible to DPP-IV degradation at the Ala2-Asp3 bond

    • Produces transient, physiological GH pulses

    • Previously approved for diagnostic use (Geref Diagnostic)

    For comparative research between sermorelin and CJC-1295 DAC, Iron Peak Peptides offers research-grade sermorelin with verified purity documentation.

    Tesamorelin (Egrifta®)

    Tesamorelin is a 44-amino-acid GHRH analog consisting of the full GHRH (1-44) sequence with a trans-3-hexenoic acid modification at the N-terminus. It is the only GHRH analog currently approved by the FDA (for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy) [18, 19].

    Key characteristics:

    • 44 amino acids plus trans-3-hexenoic acid group

    • Half-life: approximately 26–38 minutes (longer than sermorelin, far shorter than CJC-1295 DAC)

    • Partial DPP-IV resistance via N-terminal modification

    • Produces pulsatile GH secretion

    • approved (Egrifta®) for a specific clinical indication

    Researchers can obtain tesamorelin from Iron Peak Peptides for comparative GHRH analog studies.

    Comparative Summary

    Parameter

    Sermorelin

    Tesamorelin

    CJC-1295 DAC

    Length

    29 AA

    44 AA + modification

    30 AA + DAC

    Half-life

    ~10–20 min

    ~26–38 min

    ~6–8 days

    DPP-IV resistance

    None

    Partial

    Full

    Albumin binding

    No

    No

    Yes (covalent)

    GH release pattern

    Acute pulse

    Acute pulse

    Sustained elevation

    IGF-1 elevation

    Transient

    Extended (hours)

    Prolonged (9–11 days)

    FDA approval

    Withdrawn (diagnostic)

    Yes (lipodystrophy)

    No

    Regulatory status

    Research compound

    Prescription drug

    Research compound

    Synergistic Research Combinations

    Research in the growth hormone secretagogue field has explored the concept of combining GHRH analogs with growth hormone-releasing peptides (GHRPs), which act through the distinct ghrelin/GHS receptor pathway. Preclinical studies indicate that GHRH and GHRP pathways may produce synergistic effects on GH release when activated simultaneously 20, 21]. Researchers investigating these synergistic interactions may consider combining CJC-1295 DAC with GHRP compounds such as [GHRP-6 to model dual-pathway GH axis stimulation.

    CJC-1295 DAC in Current Scientific Literature

    Research interest in CJC-1295 DAC continues to expand across multiple scientific disciplines. While the original clinical development program was discontinued, the peptide remains a valuable research tool for investigating the GH/IGF-1 axis, albumin bioconjugation chemistry, and long-acting peptide pharmacology.

    Anti-Doping Detection Research

    CJC-1295 DAC has been the subject of significant research in sports anti-doping science, as GHRH analogs are prohibited by the World Anti-Doping Agency (WADA). Key studies include:

    • Henninge et al. (2010) developed methods for identifying CJC-1295 in pharmaceutical preparations using mass spectrometry, establishing reference analytical standards [12]

    • Thomas et al. (2015) expanded LC-HRMS/MS methods for detecting peptides >2 kDa, including CJC-1295, in biological matrices [7]

    • Memdouh, Gavrilović, and colleagues (2021) published a comprehensive review of advances in detecting GHRH synthetic analogs, including CJC-1295, covering both with and without DAC variants and their metabolites [15]

    These studies have advanced our understanding of CJC-1295 DAC’s metabolic fate and have established sensitive analytical methods for detecting the intact peptide and its bioconjugated forms.

    Bioconjugation and Drug Design

    The DAC technology exemplified by CJC-1295 has influenced broader developments in peptide and protein half-life extension strategies. Modern albumin-binding drug designs draw on the principles first demonstrated by CJC-1295, including:

    • Maleimide-thiol conjugation chemistry for site-specific albumin binding

    • In vivo bioconjugation as an alternative to pre-formed albumin fusion proteins

    • The concept of using endogenous proteins as pharmacokinetic “carriers” for therapeutic peptides

    Research by Zorzi et al. (2022) has explored improved maleimide linker chemistry inspired by the CJC-1295 paradigm, using monobromomaleimide linkers that offer enhanced stability of the albumin conjugate bond [22].

    Regulatory Landscape

    As of 2024, CJC-1295 DAC is not approved for any clinical indication by the U.S. FDA or other major regulatory agencies. The FDA’s Pharmacy Compounding Advisory Committee has reviewed the compound as part of broader evaluations of bulk drug substances used in compounding [23]. CJC-1295 DAC is classified as a research compound and is available for laboratory and investigational use.

    Quality Standards and Purity Verification for CJC-1295 DAC

    The structural complexity of CJC-1295 DAC — with its 30-amino-acid backbone, four non-native substitutions, and the reactive maleimidopropionic acid-lysine DAC moiety — makes quality control particularly critical. Impurities, degradation products, or incorrect synthesis can significantly impact research reproducibility.

    Critical Quality Parameters

    Researchers should evaluate CJC-1295 DAC against the following quality benchmarks:

    1. Peptide Purity (≥98% by HPLC): High-performance liquid chromatography (HPLC) remains the gold standard for assessing peptide purity. For CJC-1295 DAC, reverse-phase HPLC should confirm a single major peak with minimal related impurities.

    1. Molecular Identity (Mass Spectrometry): Electrospray ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) should confirm the expected molecular weight of approximately 3,647.28 Da (monoisotopic mass).

    1. DAC Integrity: The maleimide group must be intact and reactive. Hydrolyzed or ring-opened maleimide cannot form the covalent albumin bond that is central to CJC-1295 DAC’s mechanism of action.

    1. Amino Acid Composition: Quantitative amino acid analysis should confirm the correct ratios consistent with the CJC-1295 DAC sequence.

    1. Residual Solvent and Counterion Testing: Peptide manufacturing uses organic solvents (TFA, acetonitrile) that must be reduced to safe levels in the final product.

    1. Endotoxin Levels: For in vivo research applications, endotoxin testing (LAL assay) ensures the peptide is suitable for animal studies.

      How to Evaluate CJC-1295 DAC Quality for Research

      Not all CJC-1295 DAC on the market meets the standards required for rigorous scientific research. Here is a framework for evaluating supplier quality:

      Essential Documentation

      • quality assurance: Every batch should come with a quality assurance reporting HPLC purity, mass spectrometry confirmation, and other relevant quality parameters

      • Third-Party Testing: Independent laboratory verification provides an additional layer of confidence beyond manufacturer self-testing

      • Batch-Specific Data: COAs should reference specific lot numbers, not generic or “representative” data

      Red Flags to Watch For

      • Suppliers that do not provide COAs or only offer generic documentation

      • Purity claims below 98% (indicating suboptimal synthesis or purification)

      • Absence of mass spectrometry data confirming molecular identity

      • No information about DAC moiety integrity

      • Products not supplied in lyophilized form (liquid peptide solutions are significantly less stable)

      • Unrealistically low pricing that may indicate low-purity or counterfeit product

      The Importance of DAC Verification

      Because the DAC moiety is what distinguishes CJC-1295 DAC from Mod GRF 1-29, verifying its presence is crucial. Mass spectrometry is the most reliable method — the molecular weight difference between CJC-1295 DAC (~3,647 Da) and Mod GRF 1-29 (~3,367 Da) is approximately 280 Da, which is easily resolved by modern mass spectrometry instrumentation. Researchers should confirm that their supplier’s quality assurance specifically verifies the presence of the DAC-modified species.

      Comparing CJC-1295 DAC Sources: What Sets IronPeak Apart

      Iron Peak Peptides has established a reputation among research institutions for providing consistently high-quality peptides backed by transparent, rigorous quality documentation. For CJC-1295 DAC specifically, IronPeak differentiates itself through:

      Rigorous Testing Protocol

      Every batch of CJC-1295 DAC undergoes:

      • HPLC purity testing confirming ≥98% purity

      • Mass spectrometry verification of molecular identity (including DAC moiety)

      • Third-party independent testing through accredited analytical laboratories

      • Endotoxin screening for batches intended for in vivo research

      • Batch-specific COAs provided with every order

      Research-Optimized Packaging

      • Lyophilized format for maximum stability and shelf life

      • Argon-flushed vials to minimize oxidative degradation

      • Available in multiple quantities to accommodate different research scales

      • Properly sealed and labeled for research compliance

      Comprehensive Peptide Catalog

      Beyond CJC-1295 DAC, Iron Peak Peptides offers a full catalog of research peptides for GH axis investigation, including GHRH analogs, growth hormone-releasing peptides, and related compounds. Researchers can explore the complete selection at Buy Peptides Online USA.

      Proper Storage and Handling of CJC-1295 DAC for Research Use

      Proper storage and handling are critical for maintaining CJC-1295 DAC integrity throughout the course of a research study. The reactive maleimide group in the DAC moiety is particularly sensitive to hydrolysis and temperature-dependent degradation.

      Handling Best Practices

      • Wear appropriate PPE (gloves, lab coat)

      • Avoid exposure to extreme pH conditions (optimal pH range: 5.0–7.0)

      Frequently Asked Questions About CJC-1295 DAC

      What is CJC-1295 DAC, and how is it different from regular GHRH?

      CJC-1295 DAC is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH) that incorporates a Drug Affinity Complex (DAC) — a maleimidopropionic acid linker attached to a C-terminal lysine residue. This DAC moiety enables the peptide to form a covalent bond with circulating serum albumin after administration, extending its half-life from approximately 7–10 minutes (native GHRH) to 6–8 days. Research by Teichman et al.

      What does DAC mean in peptides?

      DAC stands for Drug Affinity Complex, a bioconjugation technology developed by ConjuChem Biotechnologies. In the context of peptides, DAC refers to a reactive chemical moiety (specifically, a maleimidopropionic acid group linked to a lysine residue) that is attached to a peptide’s structure. After administration, the maleimide group reacts with the free thiol on Cysteine-34 of serum albumin, forming a stable covalent bond. This albumin bioconjugation protects the peptide from enzymatic degradation and renal clearance, dramatically extending its circulating half-life [1, 6].

      What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?

      CJC-1295 with DAC is a 30-amino-acid peptide that includes the maleimidopropionic acid-lysine extension enabling albumin binding, giving it a half-life of 6–8 days. CJC-1295 without DAC (properly known as Modified GRF 1-29 or Mod GRF 1-29) is a 29-amino-acid peptide that shares the same core sequence and amino acid substitutions but lacks the DAC extension, resulting in a half-life of approximately 30 minutes. Both peptides activate the GHRH receptor, but they produce fundamentally different temporal profiles of GH stimulation — sustained for CJC with DAC versus pulsatile for Mod GRF 1-29 [3, 5, 7].

      How does CJC-1295 DAC affect GH pulsatility in research models?

      Research by Ionescu and Frohman (2006) demonstrated that CJC-1295 DAC increases overall GH secretion while preserving the normal pulsatile pattern. In their study, GH pulse frequency and amplitude were maintained after CJC-1295 administration, but basal (trough) GH levels were increased approximately 7.5-fold, contributing to a 46% increase in mean GH secretion and a 45% increase in IGF-1 levels [5]. This finding is significant because it indicates CJC-1295 DAC works synergistically with endogenous regulatory mechanisms rather than overriding them.

      What research studies have been conducted on CJC-1295 DAC?

      The major published studies on CJC-1295 DAC include: (1) Jetté et al. (2005) — preclinical characterization and GRF receptor activation in rat pituitary models [1]; (2) Alba et al. (2006) — growth normalization in GHRH knockout mice [2]; (3) Teichman et al. (2006) — human pharmacokinetic and pharmacodynamic trials [3]; (4) Ionescu and Frohman (2006) — GH pulsatility study in healthy adults [5]; and (5) Sackmann-Sala et al. (2009) — serum protein profiling analysis [10]. These studies collectively establish CJC-1295 DAC’s mechanism of action, pharmacokinetic profile, and physiological effects in both animal and human models.

      How does CJC-1295 DAC compare to sermorelin and tesamorelin?

      All three are GHRH analogs that activate the same GHRH receptor, but they differ substantially in structure and pharmacokinetics. Sermorelin is the unmodified GHRH (1-29) fragment with a half-life of ~10–20 minutes. Tesamorelin is a 44-amino-acid analog with an N-terminal modification giving it a half-life of ~26–38 minutes and FDA approval for HIV-associated lipodystrophy. CJC-1295 DAC, with its albumin-binding DAC moiety, has a half-life of 6–8 days — approximately 500–1,000 times longer than sermorelin. Researchers select among these analogs based on whether their protocol requires transient, moderate-duration, or sustained GH axis stimulation [3, 17, 18].

      What quality parameters should researchers verify when purchasing CJC-1295 DAC?

      Researchers should verify: (1) HPLC purity ≥98%; (2) mass spectrometry confirmation of molecular weight (~3,647 Da), which also confirms DAC moiety presence; (3) third-party independent testing; (4) batch-specific quality assurance; (5) lyophilized format for stability; and (6) endotoxin levels if the peptide will be used in in vivo studies. The molecular weight difference between CJC-1295 DAC and Mod GRF 1-29 (~280 Da) makes mass spectrometry essential for confirming the correct product identity.

      What are the recommended storage conditions for CJC-1295 DAC?

      Lyophilized CJC-1295 DAC should be stored at -20°C for long-term storage (up to 24 months) or at 2–8°C for short-term storage (up to 3 months). The lyophilized powder should be protected from light and moisture.

      Can CJC-1295 DAC be combined with other peptides in research?

      In preclinical research, CJC-1295 DAC has been studied both as a standalone compound and in the context of broader GH axis investigations involving other secretagogues. Because CJC-1295 DAC acts through the GHRH receptor pathway, it may produce complementary effects when studied alongside peptides that act through the distinct ghrelin/GHS receptor pathway, such as GHRP-6, GHRP-2, or ipamorelin [20, 21]. Such combination studies are designed to explore potential synergistic mechanisms of dual-pathway GH axis activation.

      What is the regulatory status of CJC-1295 DAC?

      CJC-1295 DAC is not approved by the FDA for any clinical indication. It was under investigation for growth hormone deficiency and lipodystrophy but clinical trials were discontinued in 2006 as a precautionary measure [11, 12]. The compound is prohibited by the World Anti-Doping Agency (WADA) in competitive sport [7, 15]. CJC-1295 DAC is available for research purposes and is sold strictly for laboratory and investigational use. Researchers should consult applicable regulations in their jurisdiction before purchasing research materials.

      References

      1. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. doi:10.1210/en.2004-1286. PMID: 15817669.

      1. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290–E1294. doi:10.1152/ajpendo.00201.2006. PMID: 16822960.

      1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. doi:10.1210/jc.2005-1536. PMID: 16352683.

      1. Thorner MO. The discovery of growth hormone-releasing hormone: an update. J Neuroendocrinol. 2008;20(6):653–654. doi:10.1111/j.1365-2826.2008.01740.x. PMID: 18601685.

      1. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. doi:10.1210/jc.2006-1702. PMID: 17018654.

      1. Léger R, Thibaudeau K, Bhardwaj M, et al. Identification of CJC-1131 as a long-lasting GLP-1 analog using DAC technology. Bioorg Med Chem Lett. 2004;14(17):4395–4398. doi:10.1016/j.bmcl.2004.06.066. PMID: 15357964.

      1. Thomas A, Walpurgis K, Tretzel L, Brinkkötter P, Fichant E, Delahaut P, et al. Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS. Drug Test Anal. 2015;7(11–12):990–998. doi:10.1002/dta.1868. PMID: 26382721.

      1. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533–1540. doi:10.1172/JCI114049. PMID: 2565342.

      1. Clemmons DR. Long-acting forms of growth hormone-releasing hormone and growth hormone: effects in normal volunteers and adults with growth hormone deficiency. Horm Res. 2007;68(Suppl 5):178–181. doi:10.1159/000110620. PMID: 18174751.

      1. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471–477. doi:10.1016/j.ghir.2009.03.001. PMID: 19386527. PMC: 2787983.

      1. Hartvig RA, Holm NB, Dalsgaard PW, Reitzel LA, Müller IB, Linnet K. Identification of peptide and protein doping related drug compounds confiscated in Denmark between 2007–2013. Scand J Forensic Sci. 2014;20(2):42–49. doi:10.2478/sjfs-2014-0003.

      1. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11–12):647–650. doi:10.1002/dta.233. PMID: 21204297.

      1. Halmos G, Schally AV. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Front Endocrinol. 2025. doi:10.3389/fendo.2025.1517735.

      1. Pal K, Melcher K, Xu HE. Structure and mechanism for recognition of peptide hormones by class B G-protein-coupled receptors. Acta Pharmacol Sin. 2012;33(3):300–311. doi:10.1038/aps.2011.170. PMID: 22266723. PMC: 4086880.

      1. Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11–12):1871–1887. doi:10.1002/dta.3183. PMID: 34665524.

      1. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906–913. doi:10.1172/JCI112679. PMID: 3093527.

      1. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139–157. doi:10.2165/00063030-199912020-00007. PMID: 18031173.

      1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. doi:10.1056/NEJMoa072375. PMID: 18057338.

      1. Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res. 2015;25(2):59–65. doi:10.1016/j.ghir.2014.12.005. PMID: 25555516. PMC: 4380639.

      1. Bowers CY. GH releasing peptides (GHRPs). In: Bentham Science Publishers. Growth Hormone Secretagogues. 1999. doi:10.2174/978160805001610601050i.

      1. Veldhuis JD, Keenan DM, Bailey JN, Adeniji A, Miles JM, Paulo R, et al. Testosterone and estradiol regulate free IGF-I, IGFBP-1, and dimeric IGF-I/IGFBP-1 concentrations. J Clin Endocrinol Metab. 2005;90:2941–2947. PMID: 15713729.

      1. Zorzi A, Linciano S, Angelini A. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics. MedChemComm. 2019;10(7):1068–1081. doi:10.1039/c9md00018d. PMID: 31391883. PMC: 6635999.

      1. U.S. Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee — CJC 1295. FDA-2024-N-4777. 2024.

      1. Chapter MC, White CM, DeRidder A, Chadwick W, Martin B, Maudsley S. Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol Ther. 2010;125(1):39–54. doi:10.1016/j.pharmthera.2009.07.006. PMID: 19686775. PMC: 2789885.

      1. Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Anal Bioanal Chem. 2016;408(12):3145–3153. doi:10.1007/s00216-016-9377-3. PMID: 26879649.

      All products mentioned in this article are sold strictly for laboratory and research purposes only. Not for human consumption. Iron Peak Peptides does not condone or promote the use of any product for purposes other than legitimate scientific research. Consult applicable regulations in your jurisdiction before purchasing research materials.

      Related Research


      ← AOD-9604 Peptide: Complete Research Guide — Mechanisms, Studies & Analysis
      Pinealon Peptide: Complete Research Guide — Neuroprotective Mechanisms & Analysis →